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Abstract. Apolipoprotein B (ApoB) levels reflect the total number potentially atherogenic 
particles that can predict cardiovascular risk. The purpose of this study was to assess if the 
ApoB in obese subjects is associated with inflammatory markers. This cross-sectional study 
was conducted on 80 obese patients at H. Adam Malik Hospital, Medan, Indonesia. 
Results: Of the 80 patients studied, the average age was 38.95 + 8.13 years old. There was a 
strong positive correlation between ApoB and triglycerides (r=0.44, p<0.001), low-density 
lipoprotein cholesterol (r=0.74, p<0.001), and HOMA-IR (r=0.31, p=0.005), however not 
with the inflammatory markers; adiponectin (r=-0.23, p=0.41) and Chemerin (r=0.021, 
p=0.851). In obesity, ApoB significantly associated with lipid and insulin resistance, as a 
risk factor for cardiovascular disease. 
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Abstrak. Kadar Apolipoprotein B (ApoB) mencerminkan jumlah total partikel aterogenik 
potensial yang dapat memprediksi risiko kardiovaskular. Tujuan dari penelitian ini adalah 
untuk menilai apakah APoB pada subjek obesitas dikaitkan dengan penanda inflamasi. 
Penelitian cross-sectional ini dilakukan pada 80 pasien obesitas di Rumah Sakit H. Adam 
Malik, Medan, Indonesia. Hasil: Dari 80 pasien yang diteliti, usia rata-rata adalah 38,95 
+ 8,13 tahun. Ada korelasi positif yang kuat antara ApoB dan trigliserida (r = 0,44, p 
<0,001), kolesterol lipoprotein densitas rendah (r = 0,74, p <0,001), dan HOMA-IR (r = 
0,31, p = 0,005), namun tidak dengan penanda inflamasi; adiponectin (r = -0,23, p = 0,41) 
dan Chemerin (r = 0,021, p = 0,851). Pada obesitas, ApoB secara signifikan terkait 
dengan resistensi lipid dan insulin, sebagai faktor risiko penyakit kardiovaskular.    
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1 Introduction 
Obesity is the accumulation of excess abnormal fat that may interfere in an optimal state of 
health. It has long been associated with an increased risk of mortality from any cause, 
predominantly through chronic diseases, such as cardiovascular disease, type 2 diabetes, and 
cancer [1]. The increment of cardiovascular disease risk is through inflammation, 
hyperlipidemia, elevated blood glucose, elevated insulin levels and high blood pressure [2], [3]. 
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In obese subjects, the risk for atherosclerotic disease is still high even after adjustment for 
established risk factors. It is thought that there are abnormalities in lipoprotein metabolism that 
do not produce hyperlipidemia and yet accelerate atherosclerosis [4]. Low-density lipoprotein 
(LDL) are atherogenic; however, when triglyceride concentration is high, LDL values are often 
not available. Therefore, other markers of lipoprotein-related to cardiovascular disease are 
needed. The measurement of lipoprotein particle, apolipoprotein B (ApoB), may improve the 
prediction of the risk of cardiovascular disease [5], [6]. 
As part of metabolic syndrome, chronic inflammation was also been associated with obesity. 
Larger adipocytes in abdominal obesity alter the ability to suppress lipolysis. Fat tissue releases 
classical adipocytokines (adiponectin, leptin, resistin) and new adipocytokines (chemerin, 
vaspin, omentin) that have a role in insulin resistance and increased cardiovascular risk [7], [8].  
Several studies examined the association between plasma lipid and inflammatory markers. 
However, the evaluation of ApoB is rarely included. Therefore, we aim to examine the 
association between ApoB and inflammatory markers in obesity. 
2 Materials and Methods 
This cross-sectional study was held in H. Adam Malik Hospital, Medan, Indonesia. Obese 
nurses (BMI > 25 kg/m2) age 30-55 were recruited. Eighty subjects agreed to participate. 
Informed consent was obtained from each subject, following approval of the local Ethical 
Committee.  Subjects with secondary illness or obesity such as acute inflammation, anemia, 
menopause, diabetes, pregnancy, cardiovascular disease, chronic kidney disease, liver 
dysfunction, smoked, consumed corticosteroid, estrogen, beta-adrenergic receptor agonists, 
nitrates, or other vasodilator agents were excluded. 
Blood samples were collected from the subjects in the morning after 10-12 hours of fasting 
combined with ethylenediaminetetraacetate (EDTA) containing heparin, then centrifuged. 
2.1 Biochemical analysis 
Serum HDL cholesterol (HDL-C), and triglycerides (TG) were analyzed by the enzymatic 
colorimetric method while Apo-B levels were assessed by the immunoassay method with 
Hitachi Modular analyzer using the Roche Diagnostic kit. Insulin levels were determined by the 
chemiluminescence immunoassay method using the DPC Immulite-I analyzer (Diagnostic 
Products Corp, Los Angeles, CA, USA) kit. 
 HOMA-IR formula = [(fasting glucose serum (mmol / l) x fasting insulin (μU / ml) / 22,5] was 
used to determine the index of insulin resistance [9].  
2.2 Statistical analysis 
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Data are presented as mean + standard deviation. All data were summarized as descriptive 
statistics. To determine whether a variable was normally distributed, we used the Shapiro-Wilk 
test. The parametric analysis was performed on variables with normal distribution, whereas the 
nonparametric test was performed on variables with the abnormal distribution. Furthermore, the 
Pearson and Spearman test were used to evaluate the correlation between variables according to 
the variable distribution. P < 0.05 was accepted as an indication of statistical significance. SPSS 
for Windows was used for the statistical analysis. 
3 Results 
This analysis included 80 obese subjects with no previous history of cardiovascular disease. The 
average age was 38.95 + 8.13 years. The traditional risk factors for cardiovascular disease, as 
well as inflammatory markers measured in this study, are presented in Table 1.  
Pearson correlation of apoB with all traditional risk factors is presented in Table 2. In general, 
apoB correlated positively with LDL-C, TG, HOMA-IR and negatively with HDL-C. ApoB 
also has a strong correlation with HOMA-IR. However, there is no correlation between apoB 
and inflammatory markers. 
Table 1 Baseline Characteristic of Obesity Subjects 
Parameters Total (mean±SD); n=80 
Age  (years) 38.95 + 8.13 
Body weight  (Kg) 75.35 ±13.49 
WC  (cm) 91.95 ± 9.59 
LDL-C (mg/dL) 138.12 ± 32,40 
HDL-C (mg/dL) 53.72 ± 16.73 
TG (mg/dL) 131.30 ± 75.92 
Adiponectin   4.42 ± 2.40 
Chemerin (ng/mL) 408.64 + 118.41 
ApoB  (g/L) 98..43 ± 20.27 
HOMA-IR  2.36 ± 3.02 
 
 
Abbreviations: WC, waist circumference; HOMA-IR: homeostasis model assessment of 
insulin resistance;; LDL-C, low density lipoprotein cholesterol; HDL-C, high density 
lipoprotein cholesterol; TG, triglycerides; ApoB: apolipoprotein B. 
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This study demonstrated that in obese subjects, plasma ApoB is positively correlated with 
several traditional risk factor for cardiovascular disease and type 2 diabetes (insulin resistance, 
LDL-C, and TG).  
ApoB is a better atherogenic parameter, compare to traditional lipid parameter (LDL-C and 
TG), because ApoB levels reflect the number of atherogenic lipoprotein particles, such as 
VLDL, LDL, and intermediate-density lipoprotein. One cross-sectional study examined the 
correlation of ApoB and risk of coronary heart disease (n=13,523), ApoB was found to be 
independently related to the risk of CHD using Framingham risk score (FRS) [10]. Moreover, 
the elevation of ApoB levels is also found in normolipidemic patients with the early coronary 
arterial disease even when total and LDL-C levels are normal [11]. 
Insulin resistance, measured with the homeostasis index (HOMA-IR), correlated with apoB in 
this study supports the association of insulin resistance with lipoprotein transport. The results of 
the present study are in agreement with the previous study on 476 subjects, demonstrating that 
apoB correlated with insulin resistance (HOMA-IR) [12]. 
Earlier studies have shown that the increment of plasma ApoB was associated with 
inflammatory markers (hsTNF-α, IL-6, hsCRP, and orosomucoid). Lipoprotein thought to have 
triggered inflammation in humans. Contradict with our finding, we did not find the correlation 
between ApoB and inflammatory markers (adiponectin and chemerin). Schlitt et al. also found 
that ApoB did not correlate with CRP  [13]. It could be as a result of the medical treatment that 
may interfere with the results. 
Our study has some limitations. As is the case in cross-sectional studies, the correlative nature 
of this analysis does not necessarily reflect causality but allows the generation of hypotheses 
Parameter r P 
Age (year) 0.209 0.063 
Body weight  (Kg) 0.90 0.420 
WC  (cm) 0.173 0.124 
LDL-C  (mg/dl) 0.74 0.000**  
HDL-C (mg/dl) -0.33 0.001** 
TG (mg/dl) 0.44 0.000** 
HOMA-IR  0.31 0.005** 
Adiponectin  -0.23 0.410 
Chemerin (ng/dl) 0.021 0.851 
Abbreviations: BMI, body mass index; WC, waist circumference; HOMA-IR: homeostasis 
model assessment of insulin resistance; LDL-C, low density lipoprotein cholesterol; HDL-C, high 
density lipoprotein cholesterol; TG, triglycerides; ApoB: apolipoprotein B. 
*P<0.05, ** P <0.01 
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regarding plausible mechanisms and the impact of our findings. Future prospective studies 
should be used to investigate the theories of this study. 
5 Conclusion 
The association between apoB and increased cardiovascular disease risks were related to lipid, 
and insulin resistance. 
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